JPMorgan increased its rating on Envista Holdings Corp. to overweight from neutral on Thursday, citing improved operational execution and a modestly higher medium-term growth framework.
The bank raised its price target on the dental products company’s shares to $32 from $29, reflecting confidence in the firm’s ability to sustain execution improvements. JPMorgan now expects Envista’s medium-term core growth framework to fall within a 2.5% to 4.5% range, up from the prior 2% to 4% outlook.
Envista is scheduled to host an investor day on September 17, where management is expected to provide further details on its strategic and financial outlook.
The upgrade follows the company’s second-quarter 2026 results, which exceeded Wall Street expectations. Adjusted earnings per share came in at $0.41, surpassing the $0.34 forecast, while revenue reached $730.5 million against an expected $716.61 million. The company also raised its full-year guidance in response to the better-than-anticipated performance.
Envista’s shares have gained 35% over the past year and 26% year-to-date, with JPMorgan noting a price-to-earnings growth ratio of 0.55. The firm’s CEO and newly appointed Chairman, Paul Keel, received a base salary increase to $1.3 million annually, alongside a one-time stock award valued at $10 million, consisting of time-based and performance-based restricted stock units.
